Lv1
60 积分 2024-09-27 加入
Anti-BCMA/GPRC5D CAR T in relapsed or refractory multiple myeloma patients with extraosseous extramedullary disease
6小时前
待确认
Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial
6小时前
已完结
B7-H3 nanobody-based CAR T cells control multiple myeloma growth, while dual BCMA/B7-H3 CAR T cells overcome antigen escape
5个月前
已完结
Developing SEMA4A-directed CAR T cells to overcome low BCMA antigen density in multiple myeloma
5个月前
已完结
Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myeloma
6个月前
已完结
皖公网安备34019202002308
